Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 325 of 3499 entries
View as:

Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00005655 Org: User:
Start: 04/28/00 End: 03/02/17 Due: 03/02/18

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase: N/A Priority: Normal
NCT ID: NCT00084682 Org: User:
Start: 06/30/05 End: 03/31/12 Due: 03/31/13

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT03880019 Org: User:
Start: 08/19/19 End: 03/06/26 Due: 03/06/27

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02101775 Org: User:
Start: 07/21/14 End: 02/20/26 Due: 02/20/27

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01271283 Org: User:
Start: 12/31/10 End: 08/31/11 Due: 08/31/12

Pilots of Self-Collection for HPV DNA Detection

Phase: N/A Priority: Normal
NCT ID: NCT00342511 Org: User:
Start: 01/09/06 End: 12/13/11 Due: 12/13/12

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00238121 Org: User:
Start: 02/28/05 End: 07/31/10 Due: 07/31/11

Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00005926 Org: User:
Start: 06/30/00 End: 12/31/00 Due: 12/31/01

Evaluating Serum Sex Steroid Hormones

Phase: N/A Priority: Normal
NCT ID: NCT00340756 Org: User:
Start: 08/06/03 End: 02/25/11 Due: 02/25/12

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT02974621 Org: User:
Start: 12/07/17 End: 07/19/25 Due: 07/19/26

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Phase: N/A Priority: Normal
NCT ID: NCT06041516 Org: User:
Start: 06/17/24 End: 10/30/29 Due: 10/30/30

Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease

Phase: N/A Priority: Normal
NCT ID: NCT00001503 Org: User:
Start: 09/19/96 End: 06/15/23 Due: 06/15/24

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03914300 Org: User:
Start: 02/10/20 End: 12/17/25 Due: 12/17/26

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02867592 Org: User:
Start: 05/18/17 End: 06/25/25 Due: 06/25/26

Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01375829 Org: User:
Start: 06/27/11 End: 03/19/26 Due: 03/19/27

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05211323 Org: User:
Start: 12/07/22 End: 12/31/25 Due: 12/31/26

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Phase: N/A Priority: Normal
NCT ID: NCT01229111 Org: User:
Start: 10/31/10 End: 03/31/14 Due: 03/31/15

Docetaxel and Flavopiridol in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00020332 Org: User:
Start: 10/31/00 End: 03/31/03 Due: 03/31/04

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03031730 Org: User:
Start: 06/14/18 End: 07/24/24 Due: 07/24/25

Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01307618 Org: User:
Start: 02/28/11 End: 02/28/15 Due: 02/28/16

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT02466971 Org: User:
Start: 05/10/16 End: 10/02/25 Due: 10/02/26

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01130519 Org: User:
Start: 05/06/10 End: 06/08/22 Due: 06/08/23

Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00504153 Org: User:
Start: 07/31/07 End: 06/30/11 Due: 06/30/12

Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery

Phase: N/A Priority: Normal
NCT ID: NCT04955808 Org: User:
Start: 02/07/17 End: 12/31/26 Due: 12/31/27

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04599634 Org: User:
Start: 12/16/21 End: 06/20/24 Due: 06/20/25